Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Delayed Quote. Delayed  - 07/27 05:35:06 pm
39.44 EUR   +0.06%
07/25 MORPHOSYS : to Host Q2 2016 Conference Call on August 1, 2016
07/04 MORPHOSYS : Receives Clinical Milestone for Start of Phase 1 Trial i..
06/20 MORPHOSYS : Reports Publication of Clinical Case Report of a Blood C..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/21/2016 07/22/2016 07/25/2016 07/26/2016 07/27/2016 Date
39.525(c) 39.14(c) 39.55(c) 39.415(c) 39.44(c) Last
55 372 42 504 59 728 88 698 82 161 Volume
+0.98% -0.97% +1.05% -0.34% +0.06% Change
More quotes
Financials (€)
Sales 2016 49,6 M
EBIT 2016 -64,6 M
Net income 2016 -44,9 M
Finance 2016 216 M
Yield 2016 -
Sales 2017 61,3 M
EBIT 2017 -46,4 M
Net income 2017 -45,0 M
Finance 2017 186 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 16,7x
EV / Sales2017 14,0x
Capitalization 1 046 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
07/25 MORPHOSYS : to Host Q2 2016 Conference Call on August 1, 2016
07/04 MORPHOSYS : Receives Clinical Milestone for Start of Phase 1 Trial in Prevention..
06/20 MORPHOSYS : Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL..
06/17 MORPHOSYS : Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL..
06/14 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
06/07 MORPHOSYS : Genedata Expands Partnership with MorphoSys to Support New Antibody ..
06/06 MORPHOSYS : Presents Updated Clinical Data for MOR202 in Multiple Myeloma and fo..
06/03 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
06/02 MORPHOSYS : AG Reports Outcome of Annual General Meeting 2016
06/01 MORPHOSYS : to Present at Six Upcoming Conferences
More news
Sector news : Biotechnology & Medical Research - NEC
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
05/03 MorphoSys AG reports Q1 results
03/11 Upcoming Events - Pivotal Data For Novartis And Perhaps Aduro Too
03/02 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2015 Results - Earnings Call Trans..
03/02 MorphoSys AG reports Q4 results
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 58,3 €
Spread / Average Target 48%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations & Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-31.63%1 150
INCYTE CORPORATION-19.82%16 315
CELLTRION, INC.--.--%10 696
LONZA GROUP AG11.40%9 743
QUINTILES TRANSNATIONA..9.89%9 029
ALKERMES PLC-35.74%7 711
More Results